Stock XRTX XORTX THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials XORTX Therapeutics Inc.

Equities

XRTX

CA98420Q3061

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.07 CAD +12.43% Intraday chart for XORTX Therapeutics Inc. 0.00% +40.34%
Apr. 22 XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal MT
Apr. 08 XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6.002 7.745 9.241 25.68 11.89 4.372
Enterprise Value (EV) 2 5.785 7.737 9.07 6.833 -2.135 0.9363
P/E ratio -1.56 x -12.3 x -6.93 x -11.8 x -1.16 x -2.01 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -5.41 x -16.5 x -8.38 x -2.38 x 0.18 x -0.19 x
EV / FCF -5.12 x 337 x -5.21 x -6.63 x 0.43 x -0.22 x
FCF Yield -19.5% 0.3% -19.2% -15.1% 230% -449%
Price to Book 18.7 x -36.6 x 7.36 x 1.53 x 1.31 x 0.94 x
Nbr of stocks (in thousands) 595 595 768 1,443 1,599 1,999
Reference price 3 10.08 13.01 12.03 17.80 7.434 2.187
Announcement Date 4/29/19 4/29/20 4/27/21 4/12/22 3/31/23 4/3/24
1USD in Million2CAD in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales - - - - - - -
EBITDA - -3.65 - - - - -
EBIT 1 - -3.65 -13.39 -6.046 -9.537 -12.92 -16.63
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income 1 -1.285 -1.652 -9.485 -2.158 - - -
Net margin - - - - - - -
EPS -2.113 -1.530 - -1.090 - - -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 4/27/21 4/12/22 3/31/23 4/3/24 - - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q4 2023 Q3 2023 Q4
Net sales - - - - - - -
EBITDA - - - - - - -
EBIT 1 - -1.609 -3.641 -3.385 -3.614 - -0.9837
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income 1 -8.355 - - - - -1.333 2.699
Net margin - - - - - - -
EPS 2 -8.010 - - - - - 1.360
Dividend per Share - - - - - - -
Announcement Date 11/29/21 4/12/22 5/13/22 8/11/22 3/31/23 11/14/23 4/3/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 4/27/21 4/12/22 3/31/23 4/3/24 - - -
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.07
Average target price
-
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XORTX THERAPEUTICS INC. Stock XORTX Therapeutics Inc.
+40.34% 8.62M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XRTX Stock
  4. Financials XORTX Therapeutics Inc.